Over the past 25 years, breast cancer incidence rates have risen globally, with the highest rates in Westernized countries. Reasons for this trend include change in reproductive patterns, increased screening, dietary changes, and decreased activity.
NeoDynamics has already developed prototypes of both the therapeutic (PRFA) as well as diagnostic device (Fourier/AS).
Further development in order to have marketable devices is being done in close cooperation with Key Opinion Leaders in respective market, both for developing the optimal launchable tools and paving the way for acceptance for both these novel and highly innovative approaches in the market place.
PRFA will initially be positioned as an option to surgery in the treatment of elderly and high risk patients, as well as adjuvant treatment for other breast cancer patients. Furthermore, PRFA is an ideal treatment option for patients with Fibroadenoma, which is the most common cause of breast mass in women younger than 35 years.
Fourier/AS will be positioned as a high end ultrasound guided core biopsy device for the diagnosis of breast cancer